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Abstract
Structured treatment interruption (STI) has been trialed as an alternative to lifelong antiretroviral therapy
(ART). We retrospectively performed single genome sequencing of the HIV-1 pol region from three patients
representing different scenarios. They were either failing on continuous therapy (CT-F), failing STI (STI-F), or
suppressing on STI (STI-S). Over 460 genomes were generated from three to five different time points over a 2-
year period. We found multiple-linked-resistant mutations in both treatment failures. However, the CT-F patient
showed a stepwise accumulation of diverse, linked mutations whereas the STI-F patient had lineage turnover
between treatment periods with recirculation of wild-type and resistant variants from reservoirs. The STI-F
patient showed a 7-fold increase in the third codon position substitution rate relative to the first and second
positions compared to a 2-fold increase for CT-F and increased purifying selection in the pol gene (62 vs. 22
sites, respectively). An understanding of intrapatient viral dynamics could guide the future direction of treat-
ment interruption strategies.
Antiretroviral therapy (ART) for human immuno-deficiency virus type 1 (HIV-1) infection is life-long.
Therefore, structured treatment interruption (STI) was pro-
posed more than a decade ago as a possible alternative
management strategy to continuous treatment (CT) to reduce
the cost and toxicity of ART.1 STI is applicable to patients in
three main scenarios: (1) those initiating therapy during acute
infection, (2) those with chronic drug-suppressed infection,
and (3) those with advanced infection and undergoing treat-
ment failure frommultidrug-resistant virus.2 It is thought that
STI, in those with suppressed viremia, could enhance re-
covery of the weakened anti-HIV immune response and
therefore provide better HIV control3 while at the same time
offering breaks off treatment to reduce side effects and cost.
In contrast, in those failing treatment the benefit from inter-
ruptions could result from the reversal of the virus population
to wild-type, which could potentially enhance success with
subsequent salvage therapy.4
Comparisons of the effects of STI and CT strategies on
treatment outcomes have shown conflicting results. On the
one hand, studies have found evidence of patient benefit from
STIwith regard to certain important clinical parameters, yet in
other studies STI appears to be inferior to CT. STI benefit has
been most evident during acute infection when the immune
system of the patient is nearly intact and where resultant ex-
pansion of virus-specific T cell immune response enables
prolonged discontinuation of highly active antiretroviral
therapy (HAART) with contained viral rebounds.5,6 One
major concern though is that the viral rebound levels might
still be above the threshold to prevent transmission.7
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However, much controversy remains over the benefits of
STI to successfully suppress chronically infected patients
with advanced disease where HIV control during interruption
critically depends on the status of the immune system. Some
studies have suggested that benefits can be realized in some
patients, especially if treatment is augmented to further
stimulate the immune system, particularly if the STI strategy
is guided by CD4+ T cell count monitoring.8 In contrast, other
studies have found no benefit and associate STI with poorer
clinical outcomes, particularly in terms of increased risk for
opportunistic infections and death.3,9 Among patients with
chronic HIV infection who are failing due to multidrug-re-
sistant HIV, most studies have found that although STI re-
sults in shifts in viral populations from resistant to wild-type
(drug-sensitive) virus, CD4+ T cell counts also decline
without accompanying virological benefits to subsequent
salvage therapy, as resistance quickly reemerges upon re-
sumption of treatment.2
Treatment interruptions are currently not recommended as
routine clinical practice, but there are genuine reasons, such
as the onset of adverse events, that necessitate treatment
disruptions. Therefore, elucidating viral evolution during
interrupted treatment is important. Studies have concentrated
on comparisons of STI with CT mostly in terms of the de-
velopment of clinical events and virological, immunological,
and quality of life treatment outcome.2,6 As yet, viral evo-
lutionally dynamics including linkages of emerging muta-
tions at a genome level during the course of treatment are still
poorly understood.
The patterns of the emergence, reversion, decay, rebound,
and polymorphism of mutations are some of the viral evo-
lutional phenomena still confounding our knowledge of HIV-
1 drug resistance. For instance, the mechanism by which
resistance persists and HIV rebounds after cessation of
treatment is not completely understood. One of the proposed
hypotheses is that these could come from a minority resistant
quasispecies in the plasma RNA and/or archived proviral
DNA reservoirs, respectively. Archived reservoirs are a
concern because they are assumed to be long-lived, thus
making recycling of drugs toward which resistance has al-
ready emerged futile.10
In this study, we assessed the impact of different treatment/
outcome scenarios on within host viral evolutionary dy-
namics. We undertook single genome sequencing of stored
plasma samples from three patients within the DART trial
in Uganda undergoing different treatment strategies: con-
tinuous therapy with emerging resistance (CT-F), structured
treatment interruptions in a patient failing to completely
suppress on ART (STI-F), and suppressing (STI-S), where
viral rebound is only during the ART off-cycles.
The ART regimen was a combination of zidovudine/la-
mivudine/nevirapine (AZT/3TC/NVP). The STI protocol
consisted of cycling on–off STI periods: 12 weeks off and 12
weeks on drugs starting from week 52 of initiating therapy
(Fig. 1). Single genome sequences for the protease (PR) and
reverse transcriptase (RT) regions were generated from
samples at three to five time points as follows: -2, 60, 72,
108, and 120 weeks before or after initiation of therapy for
both the CT-F and STI-F patients, and weeks -2, 60, and 84
for the STI-S patient. Weeks 60, 84, and 108 fell in the STI
OFF cycles, whereas the rest except week -2 were ON cy-
cles. Week -2 was a pretherapy sample (baseline). Subtyping
analysis of the PR–RT regions using the REGA HIV-1
Subtyping Tool showed that all three patients were infected
with HIV-1 subtype D.
Analyses of the intrapatient trends in the emergence of
drug-resistant mutations show differences between the pa-
tients. Overall, no major RTI drug-resistant mutations were
detected at baseline in single genomes generated from all
three patients. We found extensive, linked multidrug resis-
tance, defined as resistance to more than one class of drug,
that later emerged within both patients failing treatment (STI-
F and CT-F) irrespective of therapy structure, though the
evolutionary profiles differed between the patients. In the
STI-F patient resistance mutations emerged during the on-
treatment phase and subsequently decayed during off-treatment,
whereas for the CT-F patient a gradual accumulation and
retention of mutations over time were observed (Fig. 2A and
B). In particular, the STI-F patient developed the follow-
ing mutations by week 48: D67N/G, M184V, G190A, and
M230L, with additional mutations such as K103N and N348I
emerging subsequently.
Sampling during the off-treatment period, which was 8
weeks after stopping treatment, detected no resistance mu-
tations. Of note, not all resistant lineages reemerged in the
STI-F patient when treatment was reinitiated. Lineages
containing the D67N, M230L, and G190A mutations de-
cayed while those containing the K103N, M184V, and N348I
mutations reemerged. In the CT-F patient, mutations G190A,
M230L, and M184V also developed early together with the
T215Y mutation. However, all the resistance mutations re-
mained stable throughout the treatment period followed by
the emergence of additional mutations such as L210W. In
addition, lineages containing resistance mutations were
linked to the accessory mutations at position 178 (isoleucine
to methionine in both patients) and/or position 44 (glutamic
acid to aspartic acid in the CT-F patient). In contrast, no
resistance mutations were detected in the patient suppressing
under STI in the off-treatment phase.
FIG. 1. Schematic representing the treatment and sam-
pling protocols used in this study. The three patients were
each either (A) suppressing on structured treatment inter-
ruption (STI-S), (B) failing on structured treatment interrup-
tion (STI-F), or (C) failing on continuous therapy (CT-F).
The STI protocol was cycles of 12 weeks off and 12 weeks on
drugs [zidovudine/lamivudine/nevirapine (AZT/3TC/NVP)]
starting from week 52 of initiating therapy. Samples used in
the study were collected at different time points shown in the
boxes on top of the schematic.
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The intrapatient evolution of the HIV lineages was further
investigated using a Bayesian Markov chain Monte Carlo
(MCMC) approach under strict and relaxed molecular clock
models of evolution. At least two MCMC searches were
carried out for sequences from each patient using the
Bayesian skyline plot (BSP) demographic model and either
the general time reversible (GTR) or SRD06 codon model of
substitution. These were run for 50,000,000 generations with
sampling every 5,000th generation after a 10% burn-in. The
molecular clock model with a significant Bayes Factor (BF
>20) was used.
Figure 3 shows maximum clade credibility trees of the
single genomes from each patient. This shows that under the
STI-F patient the viruses from ON-treatment cycles (Fig. 3A,
closed symbols) were derived from a separate baseline spe-
cies to that of the OFF-treatment cycles (Fig. 3A, open
symbols). In contrast, the CT-F patient shows clonal expan-
sion with all sequences generated ON-treatment deriving
from a single baseline species that subsequently diverged into
multiple lineages containing drug-resistant mutations (Fig.
3B, closed symbols). In addition, STI-F OFF-treatment var-
iants had multiple origins from the baseline species, a pattern
similar to that observed in the STI-S OFF-treatment variants
(Fig. 3C).
Examination of intrapatient viral diversity through time
using Bayesian skyline plots revealed viral population bot-
tlenecks around the time of initiating treatment in all patients,
but the diversity steadily increased following treatment
FIG. 2. Reverse transcriptase inhib-
itor drug resistance-associated muta-
tions (DRMs) in single genomes
generated from patients failing ther-
apy. (A) Patient failing on structured
treatment interruption (STI-F) and (B)
patient failing on continuous treatment
(CT-F). The tables below each figure
show linked mutations associated with
resistance to nucleoside reverse tran-
scriptase inhibitors (NRTI) and non-
nucleoside reverse transcriptase
inhibitors (NNRTI) on each genome
and the bar graphs above depict the
proportions of single genomes con-
taining the linked mutations at each
time point. *Drug resistance-associ-
ated accessory mutations linked to
DRMs.
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failure or withdrawal of therapy (Fig. 4). However, additional
bottlenecks were observed in the CT-F patient during ther-
apy, which could indicate complicated evolutionary dy-
namics or could represent adherence problems. Overall, viral
diversity was higher in the CT-F patient, peaking toward the
end of the sampling period, compared to the STI patient,
where diversity decreased and remained low ON- and OFF-
treatment. The analysis also revealed that the intrapatient
evolutionary rates for all three treatment scenarios were
similar at 2.9 · 10-3 nucleotide substitutions per site per year
[2.3–3.6 · 10-3; 95% highest probability density (HPD)] in
STI-F patient, 3.0 · 10-3 (2.6–3.5 · 10-3; 95% HPD) in the
CT-F patient, and 1.9 · 10-3 (1.4–2.3 · 10-3; 95% HPD) in
the STI-S patient.
Using the codon-based SRD06 model of substitution we
show that in the STI-F patient the substitution rate was sig-
nificantly higher (7-fold) at the third codon position (l3rd)
relative to the first and second positions (l1st + 2nd). In
FIG. 3. Phylogenetic reconstruction of viral lineages in the patients undergoing STI or CT. Bayesian maximum clade
credibility trees (MCCT) were constructed from the single genome sequences generated from the patient on failing STI (A),
failing CT (B), or suppressing STI (C). Branches are drawn to scale with the bar and value at the bottom representing
nucleotide substitutions per site. The time of sampling of each sequence is indicated by different symbols at the tips of the
branches as shown in the legend next to the tree with open symbols representing OFF-treatment time points and closed
symbols representing ON-treatment time points.
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contrast, l3rd relative to l1st + 2nd was 2-fold higher in the CT-
F patient and intermediate in the STI-S patient at 5-fold
higher. These data suggest that the selective pressure may be
stronger in the STI-F patient than the CT-F patient and that
this is probably dominated by purifying selection. To explore
this further we estimated the site-specific selective pressures
on the RT gene, the main target of the antiretrovirals in the
treatment regimen used in the patients. We employed the
Datamonkey web interface of the HY-PHY package, which
quantifies the ratio of nonsynonymous changes to synony-
mous changes using three different algorithmic methods:
fixed effects likelihood (FEL), single likelihood ancestor
counting (SLAC), and Fast Unconstrained Bayesian Ap-
pRoximation (FUBAR), after accounting for the potentially
confounding effect of recombination. Sites identified using
two or more algorithms were considered significant.
This analysis showed a significant increase in the number
of negatively selected sites (purifying selection) in the STI-F
patient with 42 sites compared to 25 and 18 sites in the STI-S
and CT-F patients, respectively (Table 1). This includes 13
drug-resistant-associated positions: K70, F77, V118, E138,
Q151, L210, and P225 in STI-F; D67, V75, V106, V108, and
T215 in STI-S and V62 and V106 in CT-F. In contrast, only 1,
2, and 0 positively selected sites were identified in STI-F, CT-
F, and STI-S, respectively, these being V245 (STI-F) and
G196 and L210 (CT-F). The relative increase in purifying
selection was not limited to the RT gene as a similar level of
negatively selected sites was observed in the PR gene (17, 4,
and 8 in STI-F, CT-F, and STI-S, respectively).
This study provided an opportunity to explore in detail the
intrapatient evolutionary dynamics in patients undergoing
alternative treatment strategies. The patients were part of the
DART trial and were treated following the WHO guidelines
with no viral loads during treatment, so those failing re-
mained on therapy until either CD4+ count or clinical indi-
cators suggested a switch to second line was needed. The data
show significant differences in intrapatient viral dynamics
between the treatment strategies with different pathways to
the development of drug resistance.
We found that mutations conferring extensive multidrug
resistance emerged regardless of treatment structure in
the failing cases. The major mutations D67N/G, M184V,
G190A, and M230L emerged early, whereas others such as
FIG. 4. Intrapatient viral diversity during different treat-
ment strategies. Bayesian skyline plots showing the viral
diversity in the patient failing STI (A), failing CT (B), or
suppressing on STI (C). The thick solid line is the median
estimate of viral diversity (effective population size, Ne) and
the gray overlay is the 95% highest posterior density limits.
The perpendicular regions represent ON-treatment (gray)
and OFF-treatment (white) periods.
FIG. 3. (Continued).
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Table 1. Position of Sites Under Negative Selection Across the Reverse Transcriptase Gene
of Three Patients Undergoing Different Treatment Strategies and Outcomes
STI-F STI-S CT-F
Codon position FUBARa FEL SLAC FUBAR FEL SLAC FUBAR FEL SLAC
2 + +
12 + +
14 + + +
18 + + +
20 + + +
21 + + +
25 + + +
26 + + +
34 + + +
37 + + +
38 + + +
46 + + +
56 + + +
62 + +
66 + + + + +
67 + + +
70 + + +
75 + +
77 + + +
86 + + +
91 + +
92 + +
96 + +
97 + + + + +
106 + + + +
108 + +
112 + +
118 + + +
124 + +
125 + +
126 + +
127 + +
128 + + +
131 + + +
134 + +
136 + + +
138 + + +
143 + +
144 + + +
151 + +
157 + + + + + + + + +
163 + +
168 + + +
169 + +
183 + +
186 + + + + +
189 + + +
192 + + +
196 + + +
(continued)
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N348I and K103N appeared later. Previous studies have re-
ported that drug-resistant mutations persist at different rates
with M184V among those showing fast reversion and with
D67N and K103N less inclined to rapidly revert.11 M184V is
known to bring about a significant reduction in viral fitness,12
so it would be expected to revert early, whereas K103N has
little impact on replication so it can be tolerated for much
longer. However, all three mutations were shown to be ge-
netically linked and this could explain why they disappeared
concomitantly within 8 weeks after interruption of treatment
in the STI-F patient.
In the CT patient mutations emerge and then accumulate
gradually over time, whereas in the STI entire lineages can be
lost during the OFF phase not to be selected again in the
subsequent ON phases as was the case for G190A, M230L,
and D67G/N to some extent, though others such as M184V,
N348I, and K103N reemerge in subsequent ON phases. It has
been postulated that intermittent treatment, in a structured
way, as opposed to continued treatment, might be beneficial
as it delays resistance evolution by allowing reversion to
drug-sensitive wild-type virus during the periods when drug
pressure is off, thus prolonging the potency of the life-span of
the drugs.
Our study shows that this might not be entirely true but
could depend on the type of mutations and possibly the
background sequence. The reasons why some reemerged
while others did not are not clear. It could merely have been
stochastic or it could depend on the background sequence
and/or the accumulation of compensatory mutations. A larger
sample size is required to analyze this in more detail. Lastly,
drug resistance evolution was evident during the suboptimal
treatment response indicating that there is pressure from the
Table 1. (Continued)
STI-F STI-S CT-F
Codon position FUBARa FEL SLAC FUBAR FEL SLAC FUBAR FEL SLAC
197 + + +
199 + + +
201 + +
206 + + +
208 + + +
209 + + + + +
210 + + +
211 + + +
214 + + + + + +
215 + + +
220 + + + +
223 + +
225 + + +
228 + + + + +
231 + + + + +
237 + + + +
241 + + + +
242 + + +
246 + + +
247 + + +
249 + + + + + +
262 + + + +
267 + + + + +
268 + + +
276 + + + +
278 + + +
280 + + + +
281 + +
282 + + +
285 + + + +
Total 45 28 18
aSelection analysis method: fixed effects likelihood (FEL), single likelihood ancestor counting (SLAC), and Fast Unconstrained Bayesian
AppRoximation (FUBAR).
Note: positions identified using two or more selection methods were considered significant and are shown shaded in gray. Drug resistant-
associated mutations are shown in bold.
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drugs that still requires viral adjustments in order to restore
fitness. This confirms the notion that failing regimens might
not be completely useless.13
Genetic diversity plays a key role in HIV-1 adaptation
and drives the emergence of resistance, hence affecting the
response to antiretroviral treatment.14 However, it is not
known how treatment structure (continuous vs. interrupted)
drives viral evolution in terms of diversity. We found that as
expected, drug uptake results in a sharp drop in viral di-
versity compared to pretreatment levels in both cases fol-
lowed by a gradual recovery. This finding is in line with
earlier reports.15 Comparisons between the two treatment
structures at weeks 72 and 120 (on time points in the STI)
showed that CT led to the emergence of more diversified
mutation profiles, with greater persistence of mutations,
and the selection of TAMs by a different pathway. This was
perhaps reflective of the sustained drug pressure during
continuous treatment leading to a gradual and continuous
evolution as opposed to a more stochastic evolution dur-
ing treatment interruption. This resulted in a more diverse
population in the CT-F patient, which could further aid the
evolution of drug resistance.
In contrast, our data also provide additional evidence
against the notion that interrupted treatment can facilitate the
elimination of resistant genomes by allowing wild-type out-
growth of resistance lineages during the OFF-therapy time
points. Instead, our results suggest that resistant virus fades
from detection and persists either as minority variants or
archived reservoirs.
The findings from this study show significant differences
in viral dynamics between different treatment strategies
and outcomes; however, they are from a single patient in
each treatment arm, and we did not specifically investigate
for ART regimen-resistant minority variants at failure.
Thus, further studies are required using a larger cohort to
fully understand how treatment structure might have a
variably impact on host viral evolutionary dynamics. The
observed decrease in viral diversity and increased purifying
selection in STI patients could be an area that could be used
to inform the design of better treatment interruption strat-
egies for HIV.
Sequence Data
The GenBank accession numbers for the patient sequences
are as follows: CT-F: KP738731–KP738889, STI-F:
KP738890–KP739087, and STI-S: KP739088–KP739195.
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